JP2011250796A5 - - Google Patents

Download PDF

Info

Publication number
JP2011250796A5
JP2011250796A5 JP2011170509A JP2011170509A JP2011250796A5 JP 2011250796 A5 JP2011250796 A5 JP 2011250796A5 JP 2011170509 A JP2011170509 A JP 2011170509A JP 2011170509 A JP2011170509 A JP 2011170509A JP 2011250796 A5 JP2011250796 A5 JP 2011250796A5
Authority
JP
Japan
Prior art keywords
modified
irna agent
sense strand
nucleotide
nucleotides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011170509A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011250796A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2011250796A publication Critical patent/JP2011250796A/ja
Publication of JP2011250796A5 publication Critical patent/JP2011250796A5/ja
Pending legal-status Critical Current

Links

JP2011170509A 2005-07-21 2011-08-03 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法 Pending JP2011250796A (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US70147005P 2005-07-21 2005-07-21
US60/701,470 2005-07-21
US72683805P 2005-10-14 2005-10-14
US60/726,838 2005-10-14
US74831605P 2005-12-07 2005-12-07
US60/748,316 2005-12-07

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008523010A Division JP2009502138A (ja) 2005-07-21 2006-07-21 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011282081A Division JP2012061007A (ja) 2005-07-21 2011-12-22 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Publications (2)

Publication Number Publication Date
JP2011250796A JP2011250796A (ja) 2011-12-15
JP2011250796A5 true JP2011250796A5 (OSRAM) 2012-02-23

Family

ID=37683845

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2008523010A Pending JP2009502138A (ja) 2005-07-21 2006-07-21 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
JP2011170509A Pending JP2011250796A (ja) 2005-07-21 2011-08-03 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法
JP2011282081A Withdrawn JP2012061007A (ja) 2005-07-21 2011-12-22 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2008523010A Pending JP2009502138A (ja) 2005-07-21 2006-07-21 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011282081A Withdrawn JP2012061007A (ja) 2005-07-21 2011-12-22 ＲｈｏＡ遺伝子のＲＮＡｉ調節及びその使用法

Country Status (6)

Country Link
US (3) US20070044161A1 (OSRAM)
EP (2) EP2230305A1 (OSRAM)
JP (3) JP2009502138A (OSRAM)
AU (2) AU2006272808C1 (OSRAM)
CA (1) CA2607668A1 (OSRAM)
WO (2) WO2007014077A2 (OSRAM)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070044161A1 (en) * 2005-07-21 2007-02-22 Juergen Soutschek RNAi modulation of the Rho-A gene in research models
US8614309B2 (en) * 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
EP2456456A4 (en) * 2009-07-24 2013-11-20 California Inst Of Techn METHOD AND COMPOSITIONS FOR TREATING NEURAL INJURY OR DEGENERATION
WO2011021221A2 (en) * 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
US8901097B2 (en) 2009-11-08 2014-12-02 Quark Pharmaceuticals, Inc. Methods for delivery of siRNA to the spinal cord and therapies arising therefrom
EP2585594B1 (en) * 2010-06-24 2017-05-31 Quark Pharmaceuticals, Inc. Double stranded rna compounds to rhoa and use thereof
EP3599280B1 (en) 2010-10-22 2022-11-02 OliX Pharmaceuticals, Inc. Nucleic acid molecules inducing rna interference, and uses thereof
CN104755620B (zh) * 2012-05-22 2018-03-02 奥利克斯医药有限公司 具有细胞内穿透能力的诱导rna干扰的核酸分子及其用途
US9770461B2 (en) 2013-08-02 2017-09-26 California Institute Of Technology Tailored glycopolymers as anticoagulant heparin mimetics
US10227370B2 (en) 2013-08-02 2019-03-12 California Institute Of Technology Heparan sulfate/heparin mimetics with anti-chemokine and anti-inflammatory activity
WO2017035278A1 (en) 2015-08-24 2017-03-02 Halo-Bio Rnai Therapeutics, Inc. Polynucleotide nanoparticles for the modulation of gene expression and uses thereof
US11071791B2 (en) 2018-01-26 2021-07-27 Wisconsin Alumni Research Foundation Vector for gene silencing and replacement and methods of use thereof
GB201903804D0 (en) * 2019-03-20 2019-05-01 Univ Leicester Methods and kits for detecting rhoa mutations
WO2025212926A1 (en) * 2024-04-05 2025-10-09 University Of Massachusetts Aav-mediated rhoa knockdown

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990005191A1 (en) 1988-11-04 1990-05-17 Erziehungsdirektion Of The Canton Zurich Neurite growth regulatory factors
CA1341050C (en) 1988-11-04 2000-07-11 Martin E. Schwab Neurite growth regulatory factors
US5250414A (en) * 1988-11-04 1993-10-05 Erziehungsdirektion Of The Canton Zurich Diagnostic methods using neurite growth regulatory factors
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5624803A (en) * 1993-10-14 1997-04-29 The Regents Of The University Of California In vivo oligonucleotide generator, and methods of testing the binding affinity of triplex forming oligonucleotides derived therefrom
US7069634B1 (en) 1995-04-28 2006-07-04 Medtronic, Inc. Method for manufacturing a catheter
WO1996033761A1 (en) 1995-04-28 1996-10-31 Medtronic, Inc. Intraparenchymal infusion catheter system
US5735814A (en) 1996-04-30 1998-04-07 Medtronic, Inc. Techniques of treating neurodegenerative disorders by brain infusion
US7189222B2 (en) 1996-04-30 2007-03-13 Medtronic, Inc. Therapeutic method of treatment of alzheimer's disease
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US5858708A (en) 1996-08-12 1999-01-12 Bandman; Olga Polynucleotides encoding two novel human neuroendocrine-specific proteins
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
AU3134799A (en) 1998-04-16 1999-11-08 Peter Erich Braun Nevron growth inhibitory molecules or derivatives thereof used to immunize mammals thereby promoting axon regeneration
US5945290A (en) * 1998-09-18 1999-08-31 Isis Pharmaceuticals, Inc. Antisense modulation of RhoA expression
US6410323B1 (en) * 1999-08-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense modulation of human Rho family gene expression
US7169783B2 (en) * 1998-11-02 2007-01-30 Universite De Montreal (+)-Trans-4-(1-aminoethyl)-1-(4-pyridycarbamoyl)-cyclohexane and method for promoting neural growth in the central nervous system and in a patient at a site of neuronal lesion
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US6945969B1 (en) 2000-03-31 2005-09-20 Medtronic, Inc. Catheter for target specific drug delivery
US6551290B1 (en) * 2000-03-31 2003-04-22 Medtronic, Inc. Catheter for target specific drug delivery
EP1386004A4 (en) * 2001-04-05 2005-02-16 Ribozyme Pharm Inc MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID
US20030170891A1 (en) * 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002359869A1 (en) 2001-12-28 2003-07-24 The Trustees Of Columbia University In The City Of New York Pak5-related compositions and methods
DK2284266T3 (da) * 2002-11-14 2014-01-13 Thermo Fisher Scient Biosciences Inc sIRNA-MOLEKYLE MOD TP53
WO2004064737A2 (en) 2003-01-17 2004-08-05 Alnylam Pharmaceuticals Therapeutics compositions
EP2216407B1 (en) 2003-03-07 2016-01-13 Alnylam Pharmaceuticals, Inc. Therapeutic compositions
US20070054848A1 (en) * 2003-03-28 2007-03-08 Masaya Tohyama Composition and method for nerve regeneration
US20040191291A1 (en) 2003-03-28 2004-09-30 Masaya Tohyama Composition and method for nerve regeneration
US20040198640A1 (en) * 2003-04-02 2004-10-07 Dharmacon, Inc. Stabilized polynucleotides for use in RNA interference
CA2522637C (en) 2003-04-17 2014-01-21 Alnylam Pharmaceuticals, Inc. Modified irna agents
JP4991288B2 (ja) 2003-04-17 2012-08-01 アルナイラム ファーマシューティカルズ， インコーポレイテッド 二本鎖ｉＲＮＡ剤、および二本鎖ｉＲＮＡ剤の対合の安定性を調節する方法。
EP1486564A1 (de) 2003-06-13 2004-12-15 Ribopharma AG SiRNA mit erhöhter Stabilität in Serum
FR2857768B1 (fr) 2003-07-18 2006-01-06 Atmel Grenoble Sa Procede d'acquisition d'image d'empreinte digitale
WO2006043014A1 (en) * 2004-10-22 2006-04-27 Neuregenix Limited Neuron regeneration
JP2008537551A (ja) * 2005-03-31 2008-09-18 カランド ファーマシューティカルズ， インコーポレイテッド リボヌクレオチドレダクターゼサブユニット２の阻害剤およびその使用
US20070044161A1 (en) * 2005-07-21 2007-02-22 Juergen Soutschek RNAi modulation of the Rho-A gene in research models
EA014886B1 (ru) * 2006-03-31 2011-02-28 Элнилэм Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ ИНГИБИРОВАНИЯ ЭКСПРЕССИИ ГЕНА Eg5
US8598333B2 (en) * 2006-05-26 2013-12-03 Alnylam Pharmaceuticals, Inc. SiRNA silencing of genes expressed in cancer

Similar Documents

Publication Publication Date Title
JP2011250796A5 (OSRAM)
Chen et al. Chemically modified aptamers for improving binding affinity to the target proteins via enhanced non-covalent bonding
JP4584987B2 (ja) Ｃ５修飾ピリミジンを含むオリゴヌクレオチド
AU2005327517B2 (en) Oligonucleotides comprising a non-phosphate backbone linkage
TWI632155B (zh) 經胞苷－５－甲醯胺修飾之核苷酸組成物及其相關方法
TWI684596B (zh) ５-位置經修飾之嘧啶類及彼等之用途
CA2562685C (en) Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
RU2017117510A (ru) Редактирование целевой рнк
CA2784783C (en) Organic compositions to treat hsf1-related diseases
JP2014527401A5 (OSRAM)
WO2005111238A2 (en) Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
JP2006508688A (ja) ２’−置換核酸のインビトロ選択のための方法
JP2005517436A5 (OSRAM)
JP2009502138A5 (OSRAM)
KR102501963B1 (ko) 변형된 뉴클레오사이드를 포함하는 올리고뉴클레오타이드
RU2014121304A (ru) Ингибирование экспрессии вирусных генов
WO2009014705A1 (en) Compositions and methods for in vivo selex
Johannsen et al. Enzymatic polymerisation involving 2′-amino-LNA nucleotides
Seio et al. Synthesis and properties of cationic 2′-O-[N-(4-aminobutyl) carbamoyl] modified oligonucleotides
JP6703948B2 (ja) 非酵素的核酸鎖結合方法
RU2008121953A (ru) Ирнк-ингибирование репликации вируса гриппа
Park et al. Incorporation of positively charged ribonucleic guanidine linkages into oligodeoxyribonucleotides: Development of potent antisense agents
Kuwahara Progress in chemically modified nucleic acid aptamers
WO2023038126A1 (ja) 配列解析方法
Liu Studies on expression of RNA sequences embedded into a stable 5S rRNA-based scaffold